|Articles|September 16, 2014
Combination Treatment for HIV/HCV Coinfection Shown Effective in Phase 3 Trial
Results of a phase 3 trial demonstrate the effectiveness of simeprevir in combination with ribavirin and peginterferon as a treatment for patients coinfected with HIV and HCV.
Advertisement
Results of a phase 3 study published September 6, 2014 in the journal Clinical Infectious Disease demonstrates the efficacy of Janssen's simeprevir (Olysio) in combination with peginterferon and ribavirin in patients with genotype-1 hepatitis C and HIV-1 coinfection.
To read the rest of the article on
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Expands Approval of Ferric Maltol to Adolescents, Addressing a Critical Gap in Iron Deficiency Care
2
Occupational Factors Can Increase Risk of Long COVID
3
T-DXd Granted Breakthrough Therapy Designation in Post-Neoadjuvant HER2-Positive Early Breast Cancer
4
Reading Between the Codes: How Seemingly Unrelated Conditions May Signal Earlier Multiple Myeloma
5